Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type-B receptor function within pulmonary endothelial cells. Spironolactone has demonstrated...
Saved in:
Main Authors: | Zeenat Safdar, Eunah Cho |
---|---|
Format: | article |
Language: | EN |
Published: |
SAGE Publishing
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/feae43b6f1f849f2a33c67f2dc06260f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Liver abnormalities in pulmonary arterial hypertension
by: Nils P. Nickel, et al.
Published: (2021) -
Systemic arterial properties in pulmonary hypertension
by: Randi Goodman, et al.
Published: (2021) -
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
by: Micheal C. McInnis, et al.
Published: (2021) -
PeakPCO combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
by: Ci-Jun Luo, et al.
Published: (2021) -
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
by: Robert P. Frantz, et al.
Published: (2021)